Results 1 to 10 of about 13,651 (209)

Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial

EBioMedicine, 2015
Background: Abnormalities in membrane excitability and Na+ channel function are characteristic of amyotrophic lateral sclerosis (ALS). We aimed to examine the neuroprotective potential, safety and tolerability of the Na+ channel blocker and membrane ...
Susanna B Park, Steve Vucic, Matthew C Kiernan   +2 more
exaly   +3 more sources

Left atrial strain compared to volume in long-term flecainide treated patients with atrial fibrillation – a retrospective cohort study [PDF]

BMC Cardiovascular Disorders
Background Left atrial volume index (LAVI) is associated with recurrent atrial fibrillation (AF) during flecainide treatment. Nevertheless, AF patients with normal LAVI experience rhythm control failure.
Alexander Siotis, Pyotr G. Platonov, Bjarne Madsen Hardig   +2 more
doaj   +2 more sources

Reappraising Use of Flecainide for Atrial Fibrillation and Ventricular Arrhythmias in Structural Heart Disease Patients [PDF]

Medicina
Background: Flecainide, a class Ic antiarrhythmic agent, has long been contraindicated in structural heart disease (SHD) due to findings of the Cardiac Arrhythmia Suppression Trial (CAST).
Dimitrios Tsiachris, Sotirios C. Kotoulas, Ioannis Doundoulakis, Christos-Konstantinos Antoniou, Michail Botis, Konstantinos Pamporis, Nikolaos Argyriou, Aikaterini-Eleftheria Karanikola, Panagiotis Tsioufis, Athanasios Kordalis, Konstantinos Tsioufis   +10 more
doaj   +2 more sources

Flecainide

Reactions Weekly
Arunachalam K, Patel P.
europepmc   +11 more sources

Effectiveness and safety of vernakalant vs flecainide for cardioversion of atrial fibrillation in the emergency department: the VERITA study [PDF]

International Journal of Emergency Medicine
Background Vernakalant is authorized in several countries, except in the U.S., where the FDA denied its commercialization due to safety concerns, generating debate about its use.
Giuseppe Dominijanni, Antonio F. Caballero-Bermejo, Ana Sainz-Herrero, Álvaro Pineda-Torcuato, Rosa Capilla-Pueyo, Belén Ruiz-Antorán   +5 more
doaj   +2 more sources

Flecainide Paradoxically Activates Cardiac Ryanodine Receptor Channels under Low Activity Conditions: A Potential Pro-Arrhythmic Action

Cells, 2021
Cardiac ryanodine receptor (RyR2) mutations are implicated in the potentially fatal catecholaminergic polymorphic ventricular tachycardia (CPVT) and in atrial fibrillation.
Samantha C. Salvage, Esther M. Gallant, James A. Fraser, Christopher L.-H. Huang, Angela F. Dulhunty   +4 more
doaj   +1 more source

High-dose flecainide for symptomatic relief in paramyotonia congenita/severe neonatal episodic laryngospasm due to SCN4A G1306E: a case report [PDF]

Journal of Medical Case Reports
Background Severe neonatal episodic laryngospasm has been previously reported in multiple patients with the heterozygous pathogenic variant G1306E in SCN4A.
Vanessa Ogueri, Jessica Chong, Melissa Fleming, Kara Simpson, Elizabeth Sherwin, Diana Bharucha-Goebel, Christopher Spurney   +6 more
doaj   +2 more sources

Flecainide induces a sustained countercurrent dependent effect on RyR2 in permeabilized WT ventricular myocytes but not in intact cells

Frontiers in Pharmacology, 2023
Background and purpose: While flecainide is now an accepted treatment for arrhythmias associated with catecholaminergic polymorphic ventricular tachycardia (CPVT), its mechanism of action remains controversial.
Emma J. Steer, Zhaokang Yang, Moza M. Al-Owais, Hannah M. Kirton, Edward White, Derek S. Steele   +5 more
doaj   +1 more source

Case report: Use of therapeutic drug monitoring and pharmacogenetic testing as opportunities to individualize care in a case of flecainide toxicity after fetal supraventricular tachycardia

Frontiers in Pediatrics, 2023
Flecainide is a class IC antiarrhythmic utilized in prophylaxis of refractory paroxysmal supraventricular tachycardias in pediatric populations. Despite being a highly effective agent, its narrow therapeutic index increases the risk of toxicity and ...
Ronald Palmen, Ronald Palmen, Ronald Palmen, Tracy Sandritter, Tracy Sandritter, Lindsey Malloy-Walton, Lindsey Malloy-Walton, Lindsey Malloy-Walton, Christopher Follansbee, Christopher Follansbee, Christopher Follansbee, Jonathan B. Wagner, Jonathan B. Wagner, Jonathan B. Wagner, Jonathan B. Wagner, Jonathan B. Wagner   +15 more
doaj   +1 more source

Maternal, fetal, neonatal and breastmilk flecainide concentration during maternal therapy and lactation: a case report

International Breastfeeding Journal, 2023
Background Mothers requiring the antiarrhythmic agent flecainide are often advised not to breastfeed, because of the lack of data concercing neonatal effects and flecainide plasma concentrations following maternal exposure as well as via lactation.
Johanna A. van der Zande, Jérôme M.J. Cornette, Jolien W. Roos-Hesselink, Robert B. Flint   +3 more
doaj   +1 more source